Peter Kolchinsky portfolio, Q4 2024

RA Capital Management · 13F for the quarter ending Dec 31, 2024

For Q4 2024, RA Capital Management reported $7.5B across 89 US-listed positions, led by ASND (18.5%), PCVX (9.5%) and JANX (7.4%). Compared with its filing for Q3 2024, Peter Kolchinsky opened 17 new positions, added to 9, reduced 16 and sold out of 9; 47 positions did not change.

The largest purchase was a new position in SEPN ($160.2M); the largest sale, the sale of the whole position in BIIB ($229.6M).

Reported value
$7.5B
Positions
89
In the top 10
58%
Filed
Feb 14
2025

Key facts

13F portfolio value
$7.5BQ4 2024
Positions
89
Largest holding
ASND 18.5%
New positions
17
Sold out
9
Filed
Feb 14, 2025

Holdings as of (Q4 2024), filed with the SEC on . Changes are measured against the filing for Sep 30, 2024. Every tracked investor's Q4 2024 13F.

Bought and sold in Q4 2024

Peter Kolchinsky: buys and sells in Q4 2024
StockMoveSharesSizeOf portfolio
Biogen IncBIIB▼ Sold out−1.18M$229.6M3.06%
Septerna IncSEPN▲ New+7M$160.2M2.13%
Verona Pharma Plcno ticker on file
▼ Reduced 65%−3.24M$150.6M2.00%
SPDR Series TrustXBI▲ New+1.23M$110.6M1.47%
Arcellx Incno ticker on file
▲ Added 51%+935.85K$71.8M0.96%
Janux Therapeutics IncJANX▲ Added 13%+1.2M$64.2M0.86%
Evolent Health IncEVH▼ Reduced 58%−4.94M$55.5M0.74%
Ascendis Pharma A/SASND▲ Added 4.1%+402.32K$55.4M0.74%
CG Oncology IncCGON▼ Sold out−1.4M$52.7M0.70%
Recursion Pharmaceuticals IncRXRX▼ Reduced 50%−7.66M$51.8M0.69%
10X Genomics IncTXG▲ New+3.28M$47.1M0.63%
Kura Oncology IncKURA▲ New+4.45M$38.8M0.52%
Zai Lab LtdZLAB▲ New+1.3M$33.9M0.45%
Day One Biopharmaceuticalsno ticker on file
▼ Reduced 27%−2.12M$26.8M0.36%
Nurix Therapeutics IncNRIX▲ New+1.33M$25.1M0.33%
Alto Neuroscience IncANRO▼ Sold out−2.08M$23.7M0.32%
Eyepoint Pharmaceuticals IncEYPT▲ New+3.18M$23.7M0.32%
Ceribell IncCBLL▲ New+824.58K$21.3M0.28%
Newamsterdam Pharma CompanyNAMS▲ Added 9.7%+781K$20.1M0.27%
Travere Therapeutics IncTVTX▲ New+1.15M$20M0.27%
Vor Biopharma IncVOR▲ Added 74%+16.9M$18.8M0.25%
Alector IncALEC▲ New+9.7M$18.3M0.24%
Nuvalent Incno ticker on file
▼ Sold out−176.28K$18M0.24%
Apogee Therapeutics Incno ticker on file
▼ Reduced 20%−392.37K$17.8M0.24%
Bright Minds Biosciences IncDRUG▲ New+460.83K$16.6M0.22%
Bicycle Therapeutics PlcBCYC▼ Reduced 51%−1.16M$16.2M0.22%
Eledon Pharmaceuticals IncELDN▲ New+3.57M$14.7M0.20%
Tenaya Therapeutics IncTNYA▼ Sold out−6.98M$13.5M0.18%
Cervomed IncCRVO▼ Sold out−817.12K$11.9M0.16%
Aclaris Therapeutics IncACRS▲ New+4.67M$11.6M0.15%
Monopar Therapeutics IncMNPR▲ New+511.21K$11.2M0.15%
Cidara Therapeutics Incno ticker on file
▲ Added 55%+389.72K$10.5M0.14%
Structure Therapeutics IncGPCR▼ Reduced 20%−379.35K$10.3M0.14%
Dianthus Therapeutics IncDNTH▼ Reduced 20%−466.6K$10.2M0.14%
Iteos Therapeutics Incno ticker on file
▼ Reduced 34%−1.09M$8.4M0.11%
Geron CorpGERN▼ Reduced 7.1%−2.28M$8.1M0.11%
Protara Therapeutics IncTARA▲ Added 79%+1.5M$7.9M0.11%
RxSight IncRXST▼ Reduced 4.4%−173.81K$6M0.08%
Enanta Pharmaceuticals IncENTA▲ New+1.04M$6M0.08%
Bioage Labs IncBIOA▼ Reduced 41%−900K$5.2M0.07%
Enliven Therapeutics IncELVN▼ Reduced 20%−212.25K$4.8M0.06%
Adagio Medical Holdings IncADGM▼ Sold out−1.33M$3.4M0.05%
Third Harmonic Bio Incno ticker on file
▼ Reduced 25%−320.21K$3.3M0.04%
Tyra Biosciences IncTYRA▲ Added 2.1%+220.68K$3.1M0.04%
4D Molecular TherapeuticsFDMT▼ Reduced 10%−535K$3M0.04%
Metagenomi IncMGX▼ Sold out−1.31M$2.8M0.04%
AN2 Therapeutics IncANTX▼ Sold out−2M$2.1M0.03%
Allakos Incno ticker on file
▲ New+1.13M$1.4M0.02%
Scholar Rock Holding CorpSRRK▲ New+17.62K$761.4K0.01%
Regulus Therapeutics Incno ticker on file
▼ Reduced 56%−429.99K$679.4K0.01%
Scilex Holding Cono ticker on file
▲ Added 297%+775.04K$330.5K0.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q4 2024
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q3 2024
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care18.5%$1.4B10.11M$137.673+ qtrs▲ Added 4.1%
2Vaxcyte IncPCVXHealth Care9.47%$711.3M8.69M$81.863+ qtrsNo change
3Janux Therapeutics IncJANX—7.39%$555M10.37M$53.543+ qtrs▲ Added 13%
4Rhythm Pharmaceuticals IncRYTMHealth Care4.53%$340.6M6.08M$55.983+ qtrsNo change
5Legend Biotech CorpLEGN · SHHealth Care3.25%$244.3M7.51M$32.543+ qtrsNo change
6Edgewise Therapeutics IncEWTXHealth Care3.17%$237.9M8.91M$26.703+ qtrsNo change
7Newamsterdam Pharma CompanyNAMS—3.03%$227.3M8.85M$25.703+ qtrs▲ Added 9.7%
8Wave Life Sciences LtdWVE—3.00%$225.2M18.2M$12.373+ qtrsNo change
9
Arcellx Incno ticker on file · SH
—2.85%$213.8M2.79M$76.693+ qtrs▲ Added 51%
10
Avidity Biosciences Incno ticker on file · SH
—2.44%$183.2M6.3M$29.083+ qtrsNo change
11Septerna IncSEPN—2.13%$160.2M7M$22.901 qtrNew
12Dyne Therapeutics IncDYN · SH—2.00%$150.3M6.38M$23.563+ qtrsNo change
13Tyra Biosciences IncTYRA—1.97%$147.9M10.64M$13.903+ qtrs▲ Added 2.1%
14RxSight IncRXST · SH—1.71%$128.7M3.74M$34.383+ qtrs▼ Reduced 4.4%
15Bicara Therapeutics IncBCAX—1.61%$121.2M6.96M$17.422 qtrsNo change
16Lenz Therapeutics IncLENZ—1.61%$120.6M4.18M$28.873+ qtrsNo change
17Ars Pharmaceuticals IncSPRY—1.53%$114.6M10.86M$10.553+ qtrsNo change
18
89BIO Incno ticker on file · SH
—1.48%$110.9M14.18M$7.823+ qtrsNo change
19SPDR Series TrustXBI · SH—1.47%$110.6M1.23M$90.061 qtrNew
20Geron CorpGERN—1.41%$106.2M30.01M$3.543+ qtrs▼ Reduced 7.1%
21Artiva Biotherapeutics IncARTV—1.32%$99.3M9.85M$10.082 qtrsNo change
22Axsome Therapeutics IncAXSM · SHHealth Care1.13%$84.6M1M$84.613+ qtrsNo change
23
Verona Pharma Plcno ticker on file · SH
—1.09%$82.1M1.77M$46.443+ qtrs▼ Reduced 65%
24
Day One Biopharmaceuticalsno ticker on file · SH
—0.97%$72.9M5.76M$12.673+ qtrs▼ Reduced 27%
25
Apogee Therapeutics Incno ticker on file · SH
—0.95%$71.1M1.57M$45.303+ qtrs▼ Reduced 20%
26Mineralys Therapeutics IncMLYS—0.80%$59.7M4.85M$12.313+ qtrsNo change
27Praxis Precision MedicinesPRAXHealth Care0.78%$58.6M761.96K$76.963+ qtrsNo change
28Climb Bio IncCLYM—0.75%$56.6M31.42M$1.803+ qtrsNo change
29Recursion Pharmaceuticals IncRXRX · SH—0.70%$52.2M7.73M$6.763+ qtrs▼ Reduced 50%
30
Tourmaline Bio Incno ticker on file · SH
—0.69%$51.5M2.54M$20.283+ qtrsNo change
31Acrivon Therapeutics IncACRV—0.67%$50.2M8.34M$6.023+ qtrsNo change
32Fulcrum Therapeutics IncFULC—0.64%$48.1M10.23M$4.703+ qtrsNo change
3310X Genomics IncTXG · SHHealth Care0.63%$47.1M3.28M$14.361 qtrNew
34GH Research PLCGHRS—0.62%$46.8M6.69M$7.003+ qtrsNo change
35
Astria Therapeutics Incno ticker on file · SH
—0.61%$45.6M5.11M$8.943+ qtrsNo change
36Vor Biopharma IncVOR · SH—0.59%$44M39.65M$1.113+ qtrs▲ Added 74%
37Structure Therapeutics IncGPCR · SH—0.55%$41.2M1.52M$27.123+ qtrs▼ Reduced 20%
38Dianthus Therapeutics IncDNTHHealth Care0.54%$40.7M1.87M$21.803+ qtrs▼ Reduced 20%
39Pepgen IncPEPG—0.54%$40.5M10.69M$3.793+ qtrsNo change
40Evolent Health IncEVH · SH—0.54%$40.2M3.58M$11.253+ qtrs▼ Reduced 58%
41Kura Oncology IncKURA · SH—0.52%$38.8M4.45M$8.711 qtrNew
42IDEAYA Biosciences IncIDYA · SH—0.46%$34.6M1.35M$25.702 qtrsNo change
43Zai Lab LtdZLAB · ADR—0.45%$33.9M1.3M$26.191 qtrNew
44
Chimerix Incno ticker on file · SH
—0.41%$30.6M8.8M$3.483+ qtrsNo change
45
Cidara Therapeutics Incno ticker on file · SH
—0.39%$29.4M1.09M$26.882 qtrs▲ Added 55%
46MBX Biosciences IncMBX · SH—0.37%$27.9M1.51M$18.432 qtrsNo change
47Nkarta IncNKTX—0.36%$26.9M10.81M$2.493+ qtrsNo change
48Acumen Pharmaceuticals IncABOS—0.34%$25.7M14.93M$1.723+ qtrsNo change
494D Molecular TherapeuticsFDMT—0.34%$25.4M4.56M$5.573+ qtrs▼ Reduced 10%
50Nurix Therapeutics IncNRIX · SH—0.33%$25.1M1.33M$18.841 qtrNew
51Sera Prognostics IncSERA · SH—0.33%$24.7M3.03M$8.143+ qtrsNo change
52
Aerovate Therapeutics Incno ticker on file · SH
—0.32%$24.4M9.19M$2.653+ qtrsNo change
53Eyepoint Pharmaceuticals IncEYPT · SH—0.32%$23.7M3.18M$7.451 qtrNew
54Larimar Therapeutics IncLRMR · SH—0.31%$23.4M6.05M$3.873+ qtrsNo change
55Ceribell IncCBLL · SH—0.28%$21.3M824.58K$25.881 qtrNew
56Travere Therapeutics IncTVTXHealth Care0.27%$20M1.15M$17.421 qtrNew
57Enliven Therapeutics IncELVN · SH—0.25%$19.1M848.99K$22.503+ qtrs▼ Reduced 20%
58Taysha Gene Therapies IncTSHA—0.25%$18.8M10.87M$1.733+ qtrsNo change
59Alector IncALEC · SH—0.24%$18.3M9.7M$1.891 qtrNew
60Protara Therapeutics IncTARA · SH—0.24%$18M3.4M$5.283+ qtrs▲ Added 79%
61C4 Therapeutics IncCCCC—0.23%$17.6M4.88M$3.603+ qtrsNo change
62Solid Biosciences IncSLDB—0.23%$17.3M4.33M$4.003+ qtrsNo change
63Pliant Therapeutics IncPLRX · SH—0.23%$16.9M1.28M$13.173+ qtrsNo change
64Bright Minds Biosciences IncDRUG—0.22%$16.6M460.83K$36.021 qtrNew
65
Iteos Therapeutics Incno ticker on file · SH
—0.21%$16.1M2.09M$7.683+ qtrs▼ Reduced 34%
66Bicycle Therapeutics PlcBCYC · SH—0.20%$15.3M1.09M$14.003+ qtrs▼ Reduced 51%
67Eledon Pharmaceuticals IncELDN · SH—0.20%$14.7M3.57M$4.121 qtrNew
68Insmed IncINSM · SHHealth Care0.18%$13.8M200K$69.043+ qtrsNo change
69Xencor IncXNCR—0.18%$13.2M575K$22.982 qtrsNo change
70Immatics N.V.IMTX · SH—0.17%$12.4M1.75M$7.113+ qtrsNo change
71Aclaris Therapeutics IncACRS—0.15%$11.6M4.67M$2.481 qtrNew
72Monopar Therapeutics IncMNPR—0.15%$11.2M511.21K$22.001 qtrNew
73
Third Harmonic Bio Incno ticker on file · SH
—0.13%$9.9M960.62K$10.293+ qtrs▼ Reduced 25%
74Werewolf Therapeutics IncHOWL—0.12%$9.1M6.14M$1.483+ qtrsNo change
75Arvinas IncARVN · SH—0.11%$8.1M421.35K$19.173+ qtrsNo change
76Zura Bio LtdZURA · SH—0.11%$8M3.22M$2.503+ qtrsNo change
77
Perceptive Cap Solutionsno ticker on file
—0.10%$7.6M750K$10.183+ qtrsNo change
78Bioage Labs IncBIOA—0.10%$7.6M1.31M$5.792 qtrs▼ Reduced 41%
79Adicet Bio IncACET · SH—0.10%$7.3M7.54M$0.96203+ qtrsNo change
80Avalo Therapeutics IncAVTX—0.10%$7.2M967K$7.432 qtrsNo change
81Boundless Bio IncBOLD · SH—0.08%$6.3M2.18M$2.903+ qtrsNo change
82Enanta Pharmaceuticals IncENTA · SH—0.08%$6M1.04M$5.751 qtrNew
83
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.06%$4.7M333.33K$14.253+ qtrsNo change
84Surrozen IncSRZN · SH—0.05%$4.1M282.58K$14.353+ qtrsNo change
85Lexeo Therapeutics IncLXEO—0.05%$3.6M546.55K$6.583+ qtrsNo change
86
Allakos Incno ticker on file · SH
—0.02%$1.4M1.13M$1.211 qtrNew
87Scholar Rock Holding CorpSRRK · SHHealth Care0.01%$761.4K17.62K$43.221 qtrNew
88
Regulus Therapeutics Incno ticker on file · SH
—0.01%$532.2K336.84K$1.583+ qtrs▼ Reduced 56%
89
Scilex Holding Cono ticker on file · SH
—0.01%$441.8K1.04M$0.42643+ qtrs▲ Added 297%

By sector

Peter Kolchinsky portfolio by sector, Q4 2024
SectorShare of portfolioValuePositions
Health Care42.5%$3.2B12
No sector on file57.5%$4.3B77

Questions and answers

What did Peter Kolchinsky own in Q4 2024?

RA Capital Management's 13F for Q4 2024 lists 89 positions worth $7.5B. The largest: ASND (18.5%), PCVX (9.5%), JANX (7.4%), RYTM (4.5%), LEGN (3.3%).

What did Peter Kolchinsky buy in Q4 2024?

The largest purchases, by the shares bought at the quarter-end price the filing implies: SEPN (new, $160.2M), XBI (new, $110.6M), Arcellx Inc (added, $71.8M), JANX (added, $64.2M), ASND (added, $55.4M), TXG (new, $47.1M).

What did Peter Kolchinsky sell in Q4 2024?

The largest sales: BIIB (sold out, $229.6M), Verona Pharma Plc (reduced, $150.6M), EVH (reduced, $55.5M), CGON (sold out, $52.7M), RXRX (reduced, $51.8M), Day One Biopharmaceuticals (reduced, $26.8M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Dec 31, 2024 on Feb 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q4 2024: RA Capital Management 13F holdings”, data as of 14 February 2025. https://funkfolio.com/gurus/peter-kolchinsky/2024-q4

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Dec 31, 2024.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Dec 31, 2024, filed Feb 14, 2025. Changes compare share counts with the filing for Sep 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $7.5B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 3 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.